Catalyst Funds Management Pty LTD Lexicon Pharmaceuticals, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $662 Billion
- Q3 2025
A detailed history of Catalyst Funds Management Pty LTD transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 40,300 shares of LXRX stock, worth $57,226. This represents 0.01% of its overall portfolio holdings.
Number of Shares
40,300Holding current value
$57,226% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding LXRX
# of Institutions
135Shares Held
226MCall Options Held
2.5MPut Options Held
271K-
Artal Group S.A. Luxembourg, N4136MShares$193 Million100.0% of portfolio
-
Siren, L.L.C. New York, NY38.9MShares$55.3 Million2.06% of portfolio
-
Black Rock Inc. New York, NY9.89MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.52MShares$13.5 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.83MShares$5.44 Million0.0% of portfolio
About LEXICON PHARMACEUTICALS, INC.
- Ticker LXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 188,726,000
- Market Cap $268M
- Description
- Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...